Anonymous ID: f58aec May 23, 2019, 7:34 a.m. No.6566348   🗄️.is đź”—kun   >>6352 >>6372 >>6574 >>6683 >>6768 >>6898 >>6924 >>6995

U.S. new home sales fall more than expected in April

 

WASHINGTON (Reuters) - Sales of new U.S. single-family homes fell from near an 11-1/2-year high in April as prices rebounded, but demand for housing remains underpinned by declining mortgage rates and a strengthening labor market.

The Commerce Department said on Thursday new home sales dropped 6.9% to a seasonally adjusted annual rate of 673,000 units last month. March’s sales pace was revised up to 723,000 units, the highest level since October 2007, from the previously reported 692,000 units.

 

April’s decline followed three straight monthly increases

 

Economists polled by Reuters had forecast new home sales, which account for about 10% of housing market sales, would decrease 2.8% to a pace of 675,000 units in April.

 

Sales increased 7.0% from a year ago. The median new house price increased 8.8% from a year ago to $342,200 in April, the highest level since December 2017.

 

New home sales had in recent months outperformed other housing market indicators, including building permits, which had dropped for five straight months in April. New home sales are drawn from permits.

 

Economists attributed the recent strength in new home sales to declining mortgage rates. The new housing market has not been severely constrained by an inventory shortage, which has crippled sales of previously owned homes.

 

A report on Tuesday showed existing home sales fell for a second straight month in April, weighed down by a chronic shortage of more affordable houses.

 

The overall housing market hit a soft patch year and has contracted for five straight quarters. With the 30-year fixed mortgage rate dropping to around 4.07% from near an eight-year high of 4.94% in November, there is reason to be cautiously optimistic about the housing market.

 

New home sales in the South, which accounts for the bulk of transactions, declined 7.3% in April. Sales in the Midwest dropped 7.4% and those in the West tumbled 8.3%. But sales in the Northeast jumped 11.5%.

 

There were 332,000 new homes on the market last month, down 0.9% from March. While builders have stepped up construction of more affordable homes to meet strong demand in this market segment, land and labor shortages remain a challenge.

 

At April’s sales pace it would take 5.9 months to clear the supply of houses on the market, up from 5.6 months in March.

 

About two-thirds of the houses sold last month were either under construction or yet to be built.

https://www.reuters.com/article/us-usa-economy-housing/u-s-new-home-sales-fall-more-than-expected-in-april-idUSKCN1ST1QP?il=0

Anonymous ID: f58aec May 23, 2019, 8 a.m. No.6566544   🗄️.is đź”—kun   >>6622

ADMA Biosciences buy-$16m-May 21

 

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

 

Number of employees : 295 people.

https://www.marketscreener.com/ADMA-BIOLOGICS-INC-18474966/company/

 

Perceptive Advisors LLC is an employee owned hedge fund sponsor. The firm primarily provides its services to institutional investors, financial institutions, other investment funds, and high-net-worth individuals. It also manages separate client-focused equity portfolios. The firm invests in the public equity markets of the United States. It invests throughout the company’s life cycle participating in early and late stage venture, crossover rounds, leading IPOs, and public follow on financings. The firm seeks to invest in healthcare sector including biotech, pharmaceuticals, life sciences, diagnostics, medical devices and healthcare services.

https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=2117858

https://www.secform4.com/insider-trading/1368514.htm

Anonymous ID: f58aec May 23, 2019, 8:22 a.m. No.6566682   🗄️.is đź”—kun

>>6566622

another position that the hedge fund holds, neurocrine biosciences has seen it's execs sell a bit but also had another company buy into it at a reduced share price-fishing for moar money

https://www.secform4.com/insider-trading/914475.htm

Anonymous ID: f58aec May 23, 2019, 8:37 a.m. No.6566806   🗄️.is đź”—kun   >>6823

>>6566777

trips confirm evil bitch

>>6566778

>You don't think about it cause your state is not as boxed in.

they are about equal fren. You think that it is any worse where you are? Try coming here and you'll see how they are exactly alike. At least you have larger pockets of sanity…here? most are fucking insane with TDS. Add in the smug bullshit and it's no different.